Careers  |  Sign In  |  Register

The Rationale for the Administering the Seviprotimut-L Vaccine to Patients with Melanoma

Craig L. Slingluff Jr, MD, director of surgical oncology at the Emily Couric Clinical Cancer Center at the University of Virginia, discusses the use of seviprotimut-L vaccine against melanoma in the B1 Mavis study. Dr. Slingluff emphasizes the importance of developing melanoma vaccines for high-risk patients with no active disease. For a comprehensive approach, seviprotimut-L is comprised of antigens from three melanoma cell lines cultured in vitro.

Learn more by clicking here.